EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials

James P Long iD, Abhishikta Roy, Ehsan Irajizad, Kim-Anh Do, Yu Shen

Statistics in Medicine · 2026

DOI: 10.1002/sim.70731 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2026. Verfasst von James P Long und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Meta-Analysis as Topic, Models, Statistical, Early Detection of Cancer, Clinical Trials as Topic. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In meta‐analytic modeling, the functional relationship between a primary and surrogate endpoint is estimated using summary data from a set of completed clinical trials. Parameters in the meta‐analytic model are used to assess the quality of the proposed surrogate. Recently, meta‐analytic models have been employed to evaluate whether late‐stage cancer incidence can serve as a surrogate for cancer mortality in cancer screening trials. A major challenge in meta‐analytic models is that uncertainty of trial‐level estimates affects the evaluation of surrogacy, since each trial provides only estimates of the primary and surrogate endpoints rather than their true parameter values. In this work, we show via simulation and theory that trial‐level estimate uncertainty may bias the results of meta‐analytic models toward positive findings of the quality of the surrogate. We focus on cancer screening trials and the late‐stage incidence surrogate. We reassess correlations between primary and surrogate endpoints in Ovarian cancer screening trials. Our findings indicate that completed trials provide limited information regarding quality of the late‐stage incidence surrogate. These results support restricting meta‐analytic regression usage to settings where trial‐level estimate uncertainty is incorporated into the model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meta-Analysis as TopicModels, StatisticalEarly Detection of CancerClinical Trials as TopicBiomarkersHumansFemaleOvarian NeoplasmsBiasComputer SimulationUncertainty

Substanzen

Biomarkers

Autor:innen und Institutionen

  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • University of Texas School of Public Health, Houston, Texas, USA.

ORCID-Profile: James P Long

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • National Center for Advancing Translational Sciences

Zitieren

APA

Long, J. P., Roy, A., Irajizad, E., Do, K. A., & Shen, Y. (2026). Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70731

Vancouver

Long JP, Roy A, Irajizad E, Do KA, Shen Y. Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials. Statistics in Medicine. 2026. doi:10.1002/sim.70731

BibTeX
@article{Long2026,
  author = {Long, James P and Roy, Abhishikta and Irajizad, Ehsan and Do, Kim-Anh and Shen, Yu},
  title = {Bias in Meta‐Analytic Modeling of Surrogate Endpoints in Cancer Screening Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  doi = {10.1002/sim.70731}
}
Kostenlos starten →